- Home
- TWIN vs LCTX Comparison
TWIN vs LCTX Comparison
Compare TWIN & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWIN
- LCTX
- Stock Information
- Founded
- TWIN 1918
- LCTX 1990
- Country
- TWIN United States
- LCTX United States
- Employees
- TWIN N/A
- LCTX N/A
- Industry
- TWIN Industrial Machinery/Components
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TWIN Industrials
- LCTX Health Care
- Exchange
- TWIN Nasdaq
- LCTX Nasdaq
- Market Cap
- TWIN 169.9M
- LCTX 165.6M
- IPO Year
- TWIN N/A
- LCTX N/A
- Fundamental
- Price
- TWIN $11.91
- LCTX $0.88
- Analyst Decision
- TWIN
- LCTX Strong Buy
- Analyst Count
- TWIN 0
- LCTX 3
- Target Price
- TWIN N/A
- LCTX $5.67
- AVG Volume (30 Days)
- TWIN 27.4K
- LCTX 416.6K
- Earning Date
- TWIN 10-31-2024
- LCTX 08-08-2024
- Dividend Yield
- TWIN 1.37%
- LCTX N/A
- EPS Growth
- TWIN 5.33
- LCTX N/A
- EPS
- TWIN 0.79
- LCTX N/A
- Revenue
- TWIN $295,127,000.00
- LCTX $6,186,000.00
- Revenue This Year
- TWIN N/A
- LCTX N/A
- Revenue Next Year
- TWIN N/A
- LCTX $119.00
- P/E Ratio
- TWIN $15.49
- LCTX N/A
- Revenue Growth
- TWIN 6.56
- LCTX N/A
- 52 Week Low
- TWIN $10.90
- LCTX $0.77
- 52 Week High
- TWIN $18.00
- LCTX $1.61
- Technical
- Relative Strength Index (RSI)
- TWIN 42.43
- LCTX 47.00
- Support Level
- TWIN $11.72
- LCTX $0.83
- Resistance Level
- TWIN $13.23
- LCTX $0.92
- Average True Range (ATR)
- TWIN 0.49
- LCTX 0.06
- MACD
- TWIN -0.08
- LCTX 0.00
- Stochastic Oscillator
- TWIN 23.43
- LCTX 36.08
About TWIN Twin Disc Incorporated
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its products portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.